ArticleJournal of medical case reports2025
Efficacy of a personalized combination regimen combining induction chemotherapy, immunotherapy, radiotherapy, and targeted therapy for locally advanced synchronous multiple primary lung cancer: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research on the extraction of total saponins from hazel mushrooms via an ultrasound-assisted extraction method and their antitumor activity.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple primary lung cancer is becoming increasingly common in clinical practice. It is divided into synchronous multiple primary lung cancer and nonsynchronous multiple primary lung cancer on the basis of a diagnostic interval of 6 months. However, the diagnosis and treatment of multiple primary lung cancer face great challenges in clinical practice. CASE PRESENTATION: We report a case of a 66-year-old Chinese male patient with locally advanced synchronous multifocal lung cancer. In M 0 months (the time of initial diagnosis), the patient underwent two cycles of carboplatin combined with albumin-bound paclitaxel induction chemotherapy before treatment was suspended due to personal reasons. In M + 10 months, he resumed a personalized multimodal treatment regimen: induction chemotherapy combined with immunotherapy, concurrent chemoradiotherapy combined with targeted therapy, and adjuvant immunotherapy combined with targeted maintenance therapy. As of M + 72 months, positron positron emission tomography-computed tomography showed lung metastasis, but his Karnofsky Performance Status score remained at 80, and he achieved progression-free survival of 72 months. He continues to receive chemotherapy, tislelizumab immunotherapy, and recombinant human endothelin (Endostar) targeted therapy. As of M + 75 months, he has survived for 75 months without reaching the overall survival endpoint.
conclusionClinical practice should adopt a multidisciplinary treatment-based approach, integrating clinical information, imaging data, histopathological features, and molecular characteristics to formulate individualized clinical management strategies and treatment plans. Such personalized therapeutic approaches are essential to improving long-term survival rates and quality of life in patients with synchronous multifocal lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.